参考文献/References:
[1]Rodolakis A,Biliatis I,Morice P,et al.European Society of Gynecological Oncology Task Force for Fertility Preservation.Clinical Recommendations for Fertility-Sparing Management in Young Endometrial Cancer Patients.Int J Gynecol Cancer,2015,25(7):1258-1265.
[2]Colombo N,Creutzberg C,Amant F,et al.ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer:diagnosis,treatment and follow-up.Radiother Oncol,2015,117(3):559-581.
[3]Committee on Practice Bulletins-Gynecology,Society of Gynecologic Oncology.ACOG Practice Bulletin No.147:Lynch syndrome.Obstet Gynecol,2014,124(5):1042-1054.
[4]Lancaster JM,Powell CB,Kauff ND,et al.Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions.Society of Gynecologic Oncologists Education Committee.Gynecol Oncol,2007,107(2):159-162.
[5]Duska LR,Garrett A,Rueda BR,et al.EC in women 40 years old or younger.Gynecol Oncol,2001,83(2):388-393.
[6]Thigpen JT,Brady MF,Alvarez RD,et al.Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma:a dose-response study by the Gynecologic Oncology Group.J Clin Oncol,1999,17(6):1736-1744.
[7]Larson DM,Johnson KK,Broste SK,et al.Comparison of D&C and office endometrial biopsy in predicting final histopathologic grade in endometrial cancer.Obstet Gynecol,1995,86(1):38-42.
[8]Leitao MM Jr,Kehoe S,Barakat RR,et al.Comparison of D&C and office endometrial biopsy accuracy in patients with FIGO grade 1 endometrial adenocarcinoma.Gynecol Oncol,2009,113(1):105-108.
[9]Kaku T,Yoshikawa H,Tsuda H,et al.Conservative therapy for adenocarcinoma and atypical endometrial hyperplasia of the endometrium in young women:central pathologic review and treatment outcome.Cancer Lett,2001,167(1):39-48.
[10]Ushijima K,Yahata H,Yoshikawa H,et al.Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women.J Clin Oncol,2007,25(19):2798-2803.
[11]Barwick TD,Rockall AG,Barton DP,et al.Imaging of endometrial adenocarcinoma.Clin Radiol,2006,61(7):545-555.
[12]Savelli L,Ceccarini M,Ludovisi M,et al.Preoperative local staging of endometrial cancer:transvaginal sonography vs.magnetic resonance imaging.Ultrasound Obstet Gynecol,2008,31(5):560-566.
[13]Koskas M,Uzan J,Luton D,et al.Prognostic factors of oncologic and reproductive outcomes in fertility-sparing management of endometrial atypical hyperplasia and adenocarcinoma:systematic review and meta-analysis.Fertil Steril,2014,101(3):785-794.
[14]Park JY,Kim DY,Kim JH,et al.Long-term oncologic outcomes after fertility-sparing management using oral progestin for young women with EC (KGOG 2002).Eur J Cancer,2013,49(4):868-874.
[15]Minig L,Franchi D,Boveri S,et al.Progestin intrauterine device and GnRH analogue for uterus-sparing treatment of endometrial precancers and well-differentiated early endometrial carcinoma in young women.Ann Oncol,2011,22(3):643-649.
[16]Kim MK,Seong SJ,Lee TS,et al.Treatment with medroxyprogesterone acetate plus levonorgestrel-releasing intrauterine system for early-stage EC in young women:single-arm,prospective multicenter study:Korean Gynecologic Oncology Group study (KGOG2009).Jpn J Clin Oncol,2012,42(12):1215-1218.
[17]Denny L,Quinn M.FIGO Cancer Report 2015.Int J Gynaecol Obstet,2015,131 Suppl 2:S75.
[18]Eftekhar Z,Izadi-Mood N,Yarandi F,et al.Efficacy of megestrol acetate (megace) in the treatment of patients with early endometrial adenocarcinoma:our experiences with 21 patients.Int J Gynecol Cancer,2009,19(2):249-252.
[19]Erkanli S,Ayhan A.Fertility-sparing therapy in young women with EC:2010 update.Int J Gynecol Cancer,2010,20(7):1170-1187.
[20]Ushijima K,Yahata H,Yoshikawa H,et al.Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women.J Clin Oncol,2007,25(19):2798-2803.
[21]Park JY,Nam JH.Progestins in the fertility-sparing treatment and retreatment of patients with primary and recurrent endometrial cancer.Oncologist,2015,20(3):270-278.
[22]Ehrlich CE,Young PC,Stehman FB,et al.Steroid receptors and clinical outcome in patients with adenocarcinoma of the endometrium.Am J Obstet Gynecol,1988,158(4):796-807.
[23]Yamazawa K,Hirai M,Fujito A,et al.Fertility-preserving treatment with progestin and pathologic criteria to predict responses,in young women with EC.Hum Reprod,2007,22(7):1953-1958.
[24]Signorelli M,Caspani G,Bonazzi C,et al.Fertility-sparing treatment in young women with EC or atypical complex hyperplasia:a prospective single-institution experience of 21 cases.BJOG,2009,116(1):114-118.
[25]Laurelli G,Di Vagno G,Scaffa C,et al.Conservative treatment of early EC:preliminary results of a pilot study.Gynecol Oncol,2011,120(1):43-46.
[26]Perri T,Korach J,Gotlieb WH,et al.Prolonged conservative treatment of EC patients:more than 1 pregnancy can be achieved.Int J Gynecol Cancer,2011,21(1):72-78.
[27]Gallos ID,Yap J,Rajkhowa M,et al.Regression,relapse,and live birth rates with fertility-sparing therapy for EC and atypical complex endometrial hyperplasia:a systematic review andmetaanalysis.Am J Obstet Gynecol,2012,207(4):266.e1-e12.
[28]Park JY,Seong SJ,Kim TJ,et al.Pregnancy outcomes after fertility-sparing management in young women with early EC.Obstet Gynecol,2013,121(1):136-142.